칼리디 바이오테라퓨틱스CLDI 주가

♻️ 재탕[8-K] 중대 사건 — 8-K

[SCHEDULE 13G] SCHEDULE 13G

Calidi Biotherapeutics Q1 EPS $(0.43) Beats $(1.56) Estimate

Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(1.56) by 72.44 percent. This is a 80.09 percent increase over losses of $(2.16) per share

Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights

Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end of...

♻️ 재탕[8-K] 중대 사건 — 8-K

[10-Q] 분기 실적 — 10-Q

Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston

SAN DIEGO, May 13, 2026 -- Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations for Calidi Biotherapeutics, Inc. , a biotechnology company pioneering the...

[8-K] 중대 사건 — 8-K

[DEFA14A] DEFA14A — DEFA14A

[DEF 14A] 주주총회 위임장 — DEF 14A